Matteo Costacurta

Dr. Matteo Costacurta

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Molecular Cell
Verified
Journal Article
Closed access
SHSimon J Hogg
Simon J Hogg
OMOlga Motorna
Olga Motorna
LCLeonie A Cluse
Leonie A Cluse
TJTimothy M Johanson
Timothy M Johanson
HCHannah D Coughlan
Hannah D Coughlan
RJRicky W Johnstone
Ricky W Johnstone

14 May 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ELemily lelliott
emily lelliott
IKIsabella Y. Kong
Isabella Y. Kong
MZMagnus Zethoven
Magnus Zethoven
KRKelly M. Ramsbottom
Kelly M. Ramsbottom
LMLuciano G. Martelotto
Luciano G. Martelotto
SVStephin J. Vervoort
Stephin J. Vervoort
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor–positive breast cancer and are currently under evaluation across hundreds of clinical trials for other cancer types. The clinical success of these inhibitors is largely attributed to well-defined tumor-intrinsic cytostatic mechanisms, whereas their emerging role as immunomodulatory agents is less understood. Using integrated epigenomic, transcriptomic, and proteomic analyses, we demonstrated a novel action of CDK4/6 inhibitors in promoting the phenotypic and functional acquisition of immunologic T-cell memory. Short-term priming with a CDK4/6 inhibitor promoted long-term endogenous antitumor T-cell immunity in mice, enhanced the persistence and therapeutic efficacy of chimeric antigen receptor T cells, and induced a retinoblastoma-dependent T-cell phenotype supportive of favorable responses to immune checkpoint blockade in patients with melanoma. Together, these mechanistic insights significantly broaden the prospective utility of CDK4/6 inhibitors as clinical tools to boost antitumor T-cell immunity. Significance: Immunologic memory is critical for sustained antitumor immunity. Our discovery that CDK4/6 inhibitors drive T-cell memory fate commitment sheds new light on their clinical activity, which is essential for the design of clinical trial protocols incorporating these agents, particularly in combination with immunotherapy, for the treatment of cancer. This article is highlighted in the In This Issue feature, p. 2355

11 November 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
MCMatteo Costacurta
Matteo Costacurta
JHJackson He
Jackson He
PTPhilip Thompson
Philip Thompson
JSJake Shortt
Jake Shortt
Thalidomide analogues (or immunomodulatory imide drugs, IMiDs) are cornerstones in the treatment of multiple myeloma (MM). These drugs bind Cereblon (CRBN), a receptor for the Cullin-ring 4 ubiquitin-ligase (CRL4) complex, to modify its substrate specificity. IMiDs mediate CRBN-dependent engagement and proteasomal degradation of ‘neosubstrates’, Ikaros (IKZF1) and Aiolos (IKZF3), conveying concurrent antimyeloma activity and T-cell costimulation. There is now a greater understanding of physiological CRBN functions, including endogenous substrates and chaperone activity. CRISPR Cas9-based genome-wide screening has further elucidated the complex cellular machinery implicated in IMiD sensitivity, including IKZF1/3-independent mechanisms. New-generation IMiD derivatives with more potent anti-cancer properties—the CELMoDs (Cereblon E3 ligase modulators)—are now being evaluated. Rational drug design also allows ‘hijacking’ of CRL4CRBN utilising proteolysis targeting chimeras (PROTACs) to convey entirely distinct substrate repertoires. As all these chemotypes—thalidomide, IMiDs, CELMoDs and PROTACs—engage CRBN and modify its functions, we describe them here in aggregate as ‘CRBN-interacting small molecules’ (CISMs). In this review, we provide a contemporary summary of the biological consequences of CRBN modulation by CISMs. Detailed molecular insight into CRBN–CISM interactions now provides an opportunity to more effectively target previously elusive cancer dependencies, representing a new and powerful tool for the implementation of precision medicine.

3 April 2023
Verified
Other
Open access
ELemily lelliott
emily lelliott
IKIsabella Y. Kong
Isabella Y. Kong
MZMagnus Zethoven
Magnus Zethoven
KRKelly M. Ramsbottom
Kelly M. Ramsbottom
LMLuciano G. Martelotto
Luciano G. Martelotto
SVStephin J. Vervoort
Stephin J. Vervoort

3 April 2023
Verified
Other
Open access
ELemily lelliott
emily lelliott
IKIsabella Y. Kong
Isabella Y. Kong
MZMagnus Zethoven
Magnus Zethoven
KRKelly M. Ramsbottom
Kelly M. Ramsbottom
LMLuciano G. Martelotto
Luciano G. Martelotto
SVStephin J. Vervoort
Stephin J. Vervoort

3 April 2023
Verified
Other
Open access
ELemily lelliott
emily lelliott
IKIsabella Y. Kong
Isabella Y. Kong
MZMagnus Zethoven
Magnus Zethoven
KRKelly M. Ramsbottom
Kelly M. Ramsbottom
LMLuciano G. Martelotto
Luciano G. Martelotto
SVStephin J. Vervoort
Stephin J. Vervoort
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor–positive breast cancer and are currently under evaluation across hundreds of clinical trials for other cancer types. The clinical success of these inhibitors is largely attributed to well-defined tumor-intrinsic cytostatic mechanisms, whereas their emerging role as immunomodulatory agents is less understood. Using integrated epigenomic, transcriptomic, and proteomic analyses, we demonstrated a novel action of CDK4/6 inhibitors in promoting the phenotypic and functional acquisition of immunologic T-cell memory. Short-term priming with a CDK4/6 inhibitor promoted long-term endogenous antitumor T-cell immunity in mice, enhanced the persistence and therapeutic efficacy of chimeric antigen receptor T cells, and induced a retinoblastoma-dependent T-cell phenotype supportive of favorable responses to immune checkpoint blockade in patients with melanoma. Together, these mechanistic insights significantly broaden the prospective utility of CDK4/6 inhibitors as clinical tools to boost antitumor T-cell immunity.Significance:Immunologic memory is critical for sustained antitumor immunity. Our discovery that CDK4/6 inhibitors drive T-cell memory fate commitment sheds new light on their clinical activity, which is essential for the design of clinical trial protocols incorporating these agents, particularly in combination with immunotherapy, for the treatment of cancer.This article is highlighted in the In This Issue feature, p. 2355